Israel’s Authority On Medical Robotics Lifts Curtain Behind Technion’s Success Stories

Moshe Shoham talks about the innovative technologies behind surgical robotics companies Microbot Medical, XACT Robotics, Tamar Robotics and ForSight Robotics, which were all spun out of his laboratory in Israel.    

Robot hand and human finger

In the field of medical robotics, Moshe Shoham needs no introduction. An acclaimed authority of medical robotics, Shoham is one of the few Israelis to be elected to the US National Academy of Engineering and as founder and leader of the medical robotics laboratory at the Technion-Israel Institute of Technology has a long history of spin-out companies, including spine surgery company Mazor Robotics Ltd., which was acquired by Medtronic in 2018 in a $1.6bn deal.

In an interview with In Vivo, Shoham noted that medical robotics has come a long way since he started his...

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

More from New Science

Freely Available Microbiome Data ‘Atlas’ Could Provide Industry Boost

 

King’s College London has released a freely available ‘Human Gut Microbiome Atlas’ to help researchers better understand how microorganisms in the gut impact disease. 

Formation Secures Huge Series D For AI Platform Growth

 

Biopharmaceutical venture capital fundraising is on the rise in 2024. In late June, Formation Bio secured a mega financing, raising $372m via a series D round led by a16z and Sanofi. 

‘Potentially Groundbreaking’ – Grey Wolf Advances IO Technology

 

Grey Wolf Therapeutics has secured $99m via an expanded series B financing to advance its antigen modulation approach in cancer and to further explore its use in autoimmune disease indications.

The Biotech Balancing Act: Long-Term Vision Vs. Inflection Points

 
• By 

Tuyen Ong, a CEO-partner at Flagship Pioneering and CEO of Ring Therapeutics, discusses the importance of balancing short-term wins with a longer-term vision when building a biotech.   

More from In Vivo

Vigya test infogram

add a desc test

Oncology’s Next Decade: The Therapies And Players Reshaping A $400bn Future

 

Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.

Clone Test Oncology’s Next Decade: The Therapies And Players Reshaping A $400bn Future - Clone

 

Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.